This is an original JCO publication from 2010. Please visit the JCO website to access the full article.
Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer: An American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) Guideline
M. Elizabeth H. Hammond, Daniel F. Hayes, Mitch Dowsett, D. Craig Allred, Karen L. Hagerty, Sunil Badve, Patrick L. Fitzgibbons, Glenn Francis, Neil S. Goldstein, Malcolm Hayes, David G. Hicks, Susan Lester, Richard Love, Pamela B. Mangu, Lisa McShane, Keith Miller, C. Kent Osborne, Soonmyung Paik, Jane Perlmutter, Anthony Rhodes, Hironobu Sasano, Jared N. Schwartz, Fred C.G. Sweep, Sheila Taube, Emina Emilia Torlakovic, Paul Valenstein, Giuseppe Viale, Daniel Visscher, Thomas Wheeler, R. Bruce Williams, James L. Wittliff and Antonio C. Wolff
Clinical Notice (January 13, 2011): There are recommendations in the January 2007 ASCO/CAP Guideline Recommendations for HER2 Testing that must be reconciled with the April 2010 ASCO/CAP Guideline Recommendations for IHC Testing of ER/PgR so that cancer specimens will be handled in a uniform manner for the required testing of ER, PgR, and HER2 in breast cancer specimens. The points of reconciliation are discussed and summarized in a table.
|Optimal algorithm for ER/PgR testing||Positive for ER or PgR if finding of ≥ 1% of tumor cell nuclei are immunoreactive.||These definitions depend on laboratory documentation of the following:|
|Negative for ER or PgR if finding of < 1% of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PgR (positive intrinsic controls are seen).|
|Uninterpretable for ER or PgR if finding that no tumor nuclei are immunoreactive and that internal epithelial elements present in the sample or separately submitted from the same sample lack any nuclear staining.|
|Optimal testing conditions||Large, preferably multiple core biopsies of tumor are preferred for testing if they are representative of the tumor (grade and type) at resection.||Specimen should be rejected and testing repeated on a separate sample if any of the following conditions exist:|
|Specimen may also be rejected and testing repeated on another sample if:|
|Interpretation follows guideline recommendation.||Positive ER or PgR requires that ≥ 1% of tumor cells are immunoreactive. Both average intensity and extent of staining are reported.|
Image analysis is a desirable method of quantifying percentage of tumor cells that are immunoreactive.
H score, Allred score, or Quick score may be provided.
Negative ER or PgR requires < 1% of tumor cells with ER or PgR staining.
Interpreters have method to maintain consistency and competency documented regularly.
|Accession slip and report must include guideline-detailed elements.|
|Optimal tissue handling requirements||Time from tissue acquisition to fixation should be as short as possible. Samples for ER and PgR testing are fixed in 10% NBF for 6 to 72 hours. Samples should be sliced at 5-mm intervals after appropriate gross inspection and margins designation and placed in sufficient volume of NBF to allow adequate tissue penetration. If tumor comes from remote location, it should be bisected through the tumor on removal and sent to the laboratory immersed in a sufficient volume of NBF. Cold ischemia time, fixative type, and time the sample was placed in NBF must be recorded.|
|As in the ASCO/CAP HER2 guideline, storage of slides for more than 6 weeks before analysis is not recommended.|
|Time tissue is removed from patient, time tissue is placed in fixative, duration of fixation, and fixative type must be recorded and noted on accession slip or in report.|
|Optimal internal validation procedure||Validation of any test must be done before test is offered. See separate article on testing validation (Fitzgibbons et al3).|
|Validation must be done using a clinically validated ER or PgR test method.|
|Revalidation should be done whenever there is a significant change to the test system, such as a change in the primary antibody clone or introduction of new antigen retrieval or detection systems.|
|Optimal internal QA procedures||Initial test validation. See separate article on testing validation (Fitzgibbons et al3).|
|Ongoing quality control and equipment maintenance.|
|Initial and ongoing laboratory personnel training and competency assessment.|
|Use of standardized operating procedures including routine use of external control materials with each batch of testing and routine evaluation of internal normal epithelial elements or the inclusion of normal breast sections on each tested slide, wherever possible.|
|Regular, ongoing assay reassessment should be done at least semiannually (as described in Fitzgibbons et al3). Revalidation is needed whenever there is a significant change to the test system.|
|Ongoing competency assessment and education of pathologists.|
|Optimal external proficiency assessment||Mandatory participation in external proficiency testing program with at least two testing events (mailings) per year.|
|Satisfactory performance requires at least 90% correct responses on graded challenges for either test.||Unsatisfactory performance will require laboratory to respond according to accreditation agency program requirements.|
|Optimal laboratory accreditation||On-site inspection every other year with annual requirement for self-inspection.||Reviews laboratory validation, procedures, QA results and processes, and reports.|
Unsuccessful performance results in suspension of laboratory testing for ER or PgR.
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor; IHC, immunohistochemistry; QA, quality assurance; NBF, neutral buffered formalin; ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; HER2, human epidermal growth factor receptor 2.
ASCO Guideline Disclaimer: The clinical practice guidelines and other guidance published herein are provided by the American Society of Clinical Oncology, Inc. (“ASCO”) to assist practitioners in clinical decision making. The information therein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating physician, as the information does not account for individual variation among patients. Recommendations reflect high, moderate or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating physician in the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an “as is” basis, and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.